Tempus AI (NASDAQ:TEM) Price Target Cut to $60.00 by Analysts at Guggenheim

Tempus AI (NASDAQ:TEM) had its price target reduced by stock analysts at Guggenheim from $95.00 to $60.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price target would suggest a potential upside of 40.05% from the company’s previous close.

A number of other research analysts have also weighed in on the stock. Stifel Nicolaus set a $60.00 target price on shares of Tempus AI in a report on Wednesday, February 25th. Canaccord Genuity Group lowered their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, December 22nd. Morgan Stanley dropped their price objective on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. decreased their target price on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $75.92.

Tempus AI Price Performance

NASDAQ:TEM traded up $0.22 during trading hours on Monday, reaching $42.84. The stock had a trading volume of 1,532,425 shares, compared to its average volume of 5,418,551. The stock has a market capitalization of $7.66 billion, a PE ratio of -30.12 and a beta of 5.29. Tempus AI has a 52 week low of $36.22 and a 52 week high of $104.32. The company has a 50 day moving average price of $55.11 and a two-hundred day moving average price of $69.59. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13.

Insider Transactions at Tempus AI

In related news, EVP Andrew Polovin sold 10,949 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the completion of the sale, the executive vice president directly owned 126,918 shares of the company’s stock, valued at approximately $7,654,424.58. This trade represents a 7.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James William Rogers sold 10,084 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $595,460.20. Following the transaction, the chief financial officer owned 101,166 shares of the company’s stock, valued at approximately $5,973,852.30. The trade was a 9.06% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 568,841 shares of company stock valued at $32,579,611. Company insiders own 26.27% of the company’s stock.

Institutional Trading of Tempus AI

A number of large investors have recently made changes to their positions in the stock. Renaissance Capital LLC raised its stake in Tempus AI by 26.9% in the third quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock worth $6,793,000 after buying an additional 17,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Tempus AI by 1,459.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after acquiring an additional 94,783 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new stake in Tempus AI during the 3rd quarter valued at $1,695,000. Vanguard Group Inc. increased its holdings in shares of Tempus AI by 22.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after acquiring an additional 1,706,837 shares during the period. Finally, Krane Funds Advisors LLC increased its holdings in shares of Tempus AI by 218.2% in the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after acquiring an additional 19,358 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.